Centrient Pharmaceuticals
Robin N. Koenig has extensive work experience in the pharmaceutical industry. From 2019 to the present, they have worked at Centrient Pharmaceuticals in various roles, including Global Vice President of Statins, Cephalosporins, Nystatin, Distribution & Key Account Management and Global Franchise Director for Statins & Cephalosporins. Before joining Centrient Pharmaceuticals, they served as the CEO of KONAPHARMA Ltd. from 2017 to 2019. Prior to that, they held multiple positions at Sandoz, including Country Head Sandoz Kazakhstan and Head of Portfolio & Business Development for the Central & Eastern Europe region.
Robin N. Koenig has a diverse education history. In 1995 to 1998, they attended Université de Fribourg - Universität Freiburg where they studied Medien und Kommunikationswissenschaften. Later on, in 1997 to 1998, they joined Swiss Army, specializing in Artillery. In 2003 to 2005, they pursued an eidg.dipl.Kommunikationsleiter at SAWI, focused on Marketing. In 2008, they completed an Executive Education Program in Organisationsführung at Babson College. In 2010, they obtained an MBA in General Management from University of St.Gallen. Finally, in 2015, they participated in the Executive Education Program in Finance at Harvard Business School.
This person is not in any offices
Centrient Pharmaceuticals
2 followers
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.